Kimmy Delahunty’s Post

Excited to learn from the rare disease community in Philadelphia at the Rare Disease Summit 3/19-3/21. Let's create powerful partnerships, explore how we can advance orphan therapeutics with Real World Evidence, and understand how AI can improve your efficiencies and outcomes. If you will be in town, or attending the conference and want connect over some coffee or a bite to eat. I look forward to meeting some industry experts. #rwe #ai #raredisease #orphandrugs #bigdata #personalizedmedicine #outcomesresearch #realworldevidence #realworlddata OM1, Inc.

Did you know that over 6,000 rare diseases have been identified? The journey to diagnosis for these conditions can often be long and complex, with many patients facing mis- or underdiagnoses. Enter AI 🚀 - a game-changer in the realm of healthcare! At OM1, we're harnessing the power of AI to transform the way we identify rare disease patients. Our cutting-edge tool, PhenOM™, combined with our Real-World Data Cloud, is paving the way for faster and more accurate diagnoses. By identifying patterns in databases and navigating the complexities of real-world data, OM1 offers robust solutions to the challenges faced in rare disease research. Our AI-driven approach is not just about technology; it's about making a real difference in patients' lives by shortening the time to diagnosis. Interested in how OM1 can revolutionize rare disease research? Dive deeper into our innovative solutions and join us in making healthcare better for everyone. #OM1 #PhenOM #AIInHealthcare #RareDiseaseResearch #InnovationInHealth

Great article on our approach!

🔥🔥🔥AI is so hot right now and especially in healthcare🔥🔥🔥 After our 🗽CUNY Public Health Innovation Accelerator win and successful Investor Day Plug and Play pitch, we have received significant interest. Thus we decided to raise a friends/family/advisor round to fund the purchase of specialized data to build our AI machine learning algorithm to detect high-pack-year smokers that are susceptible to getting lung cancer. We’ve had 165+ investors reach out. We don’t have time to meet with everyone so instead we’re sharing our investor presentation with the world. More than anything we hope this transparency builds customer trust. ▶️Watch a Youtube investor presentation to learn more about our company. https://lnkd.in/gM-nkdwU 🎀1 in 2 Men and 1 in 3 Women Will Develop Cancer in Their Lifetime...🎀 We want to be there and provide early detection services so that when you or your family members get cancer, we will catch it early enough to make a difference. Our life's work is Oatmeal Health: an AI-enabled specialty cancer screening clinic focused on providing early-detection, health equity, and care coordination services for Federally Qualified Health Centers (FQHCs) and Health Plans. We are fundamentally changing the lives of underserved patients through early identification, preventative screening, and comprehensive high-touch value-based care services, starting with lung cancer. Oatmeal Health's co-founder and CEO, Ty Vachon M.D., (Navy Veteran/Radiologist/Primary Care) was inspired to create the company during his time in the Navy, where he observed the challenges of preventative care and the need for a proactive approach to cancer screening. Both founders, Ty Vachon M.D., and Jonathan Govette, were also motivated by personal experiences of losing family members to lung cancer due to a lack of access to and education about eligibility requirements. Ty Vachon M.D. and I spent the last 12 mo in conversations with well over 100 health centers, health executives, and advisors to learn about the main challenges they are facing in providing care to a diverse population. One of the significant challenges is the lack of resources, time, and technology at Federally Qualified Health Centers (FQHCs) to effectively provide widespread preventative services. Due to the limited time per appointment, which typically averages between 13 to 16 minutes, FQHC's focus primarily revolves around reactive services based on the patient's immediate concerns during the appointment, with little room for anything beyond that. Consequently, the services provided by Medicare and Medicaid are currently underutilized. Senior individuals tend to postpone seeking medical attention until their conditions worsen, leading them to resort to emergency room visits, which incur much higher costs, around $45,000, compared to the standard $50 Medicare visit. In cases like lung cancer, the costs escalate significantly, reaching as high as $282,000 over a lifetime.

Just wrapped up a thought-provoking panel discussion on Rare Disease Strategy; Evolution, Needs, and Future Steps at #CAPTConference2023. Some priorities raised by the panelists included the need for: 1) An integrated, coordinated, and timely approach to care 2) Investing in innovative therapies, genomic testing, and other infrastructure to support the future of personalized medicine 3) Enhancing our ability to collect and use #realworlddata 4) Viewing these investments in the context of not only improving care for patients with Rare Disorders, but in enabling healthcare transformation that improves the lives for ALL patients My take-away is that we have a collective common mission to make a positive impact, and discussions like these help bring us closer to that goal. Thank you to our panelists, Durhane Wong-Rieger, Daniel MacDonald, Bob McLay, Don Husereau, and Dr. Kevin Kuo for sharing their expertise, to the Canadian Association for Population Therapeutics for putting on another great conference, and to all the attendees who joined us. #RareDisease #FutureOfMedicine #RealWorldEvidence

Action + Impact. It's what we do.

#Genedrive2023 A Year in Review - February February might be the shortest month of the year, but it was one of the most celebrated. 🎆 Genedrive started to witness all the hard work of our partnership with Manchester University NHS Foundation Trust for the Genedrive® MT-RNR1 ID Kit, come to fruition with the recognition from the NICE - National Institute for Health and Care Excellence Early Value Assessment during the public consultation for the recommendation of our product. This was a huge step forward for Genedrive, and for pharmacogenetic point of care testing. 💙 🔗 A reminder of the full article can be found here: https://lnkd.in/gnQDEe8K #GDR #Genedrive2023 #partnership #collaboration #genetics #diagnostics #pharmacogenetics

It was my great pleasure to organize & moderate the panel session on "Platform Trials for Efficient Evidence Generation at the Global Scale: Looking Beyond Public Health Crisis" at #RISW2023! Thank you Dr. Joan Buenconsejo (BMS) for sharing the lessons learnt from an interview project with the PIs and statisticians of several major COVID platform trials, and Dr. Michael Proschan (NIH) (on behalf of Dr. Lori Dodd) for sharing experience from NIH platform trials! I deeply appreciate our distinguished group of panelists, including Dr. Gregory Levin (FDA/CDER), Dr. Scott Berry (Berry Consultant), Dr. Estelle Russek-Cohen (ERCStatsLLC), Dr. Olivier Collignon (GSK[UK]), for having very interactive and civilized discussions on some critical and perhaps controversial topics 😉 Related reference for those who are interested: - Buenconsejo et al (2023). Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics. Contemp Clin Trials. doi: 10.1016/j.cct.2023.107292. - Collignon et al (2021). Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome. Clin Pharmacol Ther. doi: 10.1002/cpt.2183. - Berry et al (2015). The platform trial: an efficient strategy for evaluating multiple treatments. JAMA doi: 10.1001/jama.2015.2316.

🌍 On the road to #RareDiseaseDay, let's shed light on the millions impacted by rare diseases, a number surpassing those affected by cancer and Alzheimer's combined. At AstraZeneca, we're diving deep into the complexities of rare disease research, embracing the challenges with innovation and resilience. 🧬 🤝 With fewer than 10% of these diseases having approved treatments, our commitment to finding solutions is more crucial than ever. By integrating insights directly from the rare disease community, we're not just conducting research; we're leading a movement towards patient-centric clinical trials and breakthroughs in healthcare. 🚀 Join us in this journey. Let's make a tangible difference together. Read more: https://lnkd.in/eeR-cjMA

🌍 On the road to #RareDiseaseDay, let's shed light on the millions impacted by rare diseases, a number surpassing those affected by cancer and Alzheimer's combined. At AstraZeneca we're diving deep into the complexities of rare disease research, embracing the challenges with innovation and resilience. 🧬 🤝 With fewer than 10% of these diseases having approved treatments, our commitment to finding solutions is more crucial than ever. By integrating insights directly from the rare disease community, we're not just conducting research; we're leading a movement towards patient-centric clinical trials and breakthroughs in healthcare. 🚀 Join us in this journey. Let's make a tangible difference together. Read more: https://lnkd.in/eYCFpkYi